Disturbance of plasma thyroid hormone levels after experimental liver transplantation. Is there an association with primary graft nonfunction?

It has been suggested recently that preoperative plasma thyroid hormone levels may be used to predict the success of liver transplantation in prospective recipients and also perhaps that postoperative levels may be used to identify rejection. In the present study of unimmunosuppressed porcine recipients of liver allografts, two groups of animals were identified--those that died within five days postoperatively and the other group that were longer survivors. On the first postoperative day plasma levels of total and free T4 and total and free T3 declined and of total rT3 increased. In survivors these levels returned towards normal within three days, while they persisted in nonsurvivors. As there was no obvious cause of graft failure in nonsurvivors, the state might be considered to represent primary graft nonfunction in pigs, and the changes in plasma thyroid hormone levels may be predictive of this condition; a study in patients may confirm this.

Tumour marker CA125 levels in a variety of benign and malignant conditions.

The levels of tumour marker CA125 were established in 515 patients with a variety of benign and malignant conditions. With a specificity of 60.3% and an overall sensitivity for malignant tumours of 54% (extra-ovarian serous papillary carcinomas 100%), it is the most reliable tumour marker at present available for epithelial ovarian cancer and is of considerable value in the management of this condition when considered in conjunction with other clinical measurements.

The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas.

From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7% of cases, mucinous tumors 20.4%, endometrioid tumors 16%, and other epithelial tumors 19.4%. Tumors of low malignant potential and benign epithelial cystadenomas were not included. For this study the upper limit of normal for CA 125 was 20 U/ml. Thirty-six were new cases. In this group the initial CA 125 levels greater than 20 U/ml, greater than 35 U/ml, and greater than 65 U/ml were 97.2, 94.4, and 86.1%, respectively. When mucinous types were excluded the specificity rate did not change significantly. There was no significant difference in initial CA 125 levels between early stages I and II and late stages III and IV. No correlation between tumor bulk and the serum level of antigen was observed. The remaining 62 patients were being followed and in this group 50 were considered to be in remission. Six cases in the remission group had elevated CA 125 levels greater than 20 U/ml and 5 of these developed clinical recurrence. The correlation between the clinical status and concordant fluctuations in the serum levels of CA 125 in all histological types was 87.8 and 93.5% when 10 cases of mucinous tumors were excluded. The contingency coefficient was 0.746. Seven SLOs were performed. All had CA 125 levels less than 20 U/ml and the mean was 6.9 U/ml. Only 1 case was positive with microscopic disease. In our experience CA 125 was invaluable in the management and follow-up of patients with ovarian carcinoma especially for the early detection of recurrent disease and for the monitoring of patients on therapy.

The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary.

The value of cancer antigen-125 (CA-125) as a tumor marker for malignant germ cell tumors (MGCT) of the ovary was investigated and compared with the other recognized tumor markers (human chorionic gonadotrophin (hCG), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) isoenzymes. In the 10 months following June 1984, 4 new cases with MGCT and 1 patient with active disease on treatment were evaluated. In all cases prior to planned surgery the levels of CA-125 were significantly elevated. The serum values ranged from 154 to 617 U/ml (normal less than 20 U/ml). In 1 case (pure dysgerminoma) CA-125 was the only tumor marker. In 3 patients (2 mixed germ cell tumors and 1 immature teratoma) serum LDH (LD 1, 2, and 3) was elevated, and AFP was elevated in 1 of these. In the fifth case (mixed germ cell tumor), on treatment, serum AFP was used to monitor the disease. Four patients underwent cytoreductive surgery followed by combination chemotherapy. The changes in the serum levels of CA-125 paralleled those of the other tumor markers while on therapy. In our experience CA-125 is an invaluable indicator of the clinical status of the patient and could be a new tumor marker in patients with MGCT.